Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial] (POUDER)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01879878 |
Recruitment Status : Unknown
Verified May 2015 by Peter Schemmer, Heidelberg University.
Recruitment status was: Recruiting
First Posted : June 18, 2013
Last Update Posted : May 28, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pancreatic Ductal Adenocarcinoma | Dietary Supplement: Verum, broccoli sprout grain Dietary Supplement: placebo | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial] |
Study Start Date : | December 2013 |
Estimated Primary Completion Date : | December 2015 |
Estimated Study Completion Date : | December 2015 |

Arm | Intervention/treatment |
---|---|
Experimental: Verum, broccoli sprout grain
Active sulforaphane distributed in capsules each containing broccoli sprout grain
|
Dietary Supplement: Verum, broccoli sprout grain
Patients will be randomly classified into two groups - verum and placebo. The patients in the experimental arm will receive capsules with broccoli sprout grain containing a total of 90mg sulforaphane active substance per day over one year as nutrition supplement whereas patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution.
Other Name: glucoraphanin |
Placebo Comparator: Placebo
Inactive substances (methylcellulose) with identical capsule and portion distribution
|
Dietary Supplement: placebo
Patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution as the experimental arm. |
- Feasibility of a randomized controlled trial [ Time Frame: One year ]Main objective is to test the feasibility of a randomized controlled trial regarding the application of freeze-dried broccoli sprouts rich in sulforaphane and quercetin in patients with advanced, surgically non-resectable pancreatic ductal adenocarcinoma treated with palliative chemotherapy
- Disease status (imaging and tumor markers) [ Time Frame: One year ]Disease status (cancer progress or regress): CT-imaging staging (if available) and serum tumor markers (CEA and CA-19-9) peaks as additional parameters that provide insight into disease status.
- Substance bioavailability [ Time Frame: One year ]Urine analysis as marker of substance systemic bioavailability (conversion of the precursor glucoraphanin to the active drug substance sulforaphane). Urine analysis serves as control of the regular intake of the test substance as well.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Advanced, surgically non-treatable pancreatic ductal adenocarcinoma (surgical exploration, intraoperative biopsy but also palliative bypass interventions (bileodigestive anastomosis and/or gastroenterostomy because of preoperative cholestasis or impaired gastric emptying due to tumor-mass effect)
- Intact gastric emptying
- Written informed consent
- Patients ≥18 years of age
- Palliative chemotherapy
Exclusion Criteria:
- Intolerance to broccoli or its ingredients
- Impaired mental status or language problems / barriers

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01879878
Contact: Peter Schemmer, Prof. Dr. med. | +49 6221 566205 | peter.schemmer@med.uni-heidelberg.de | |
Contact: Vladimir J. Lozanovski, M.D. | +49 6221 5636439 | vladimir.lozanovski@med.uni-heidelberg.de |
Germany | |
Dept. of General and Transplant Surgery, University Hospital of Heidelberg, Germany | Recruiting |
Heidelberg, Germany, 69120 | |
Contact: Vladimir J. Lozanovski, M.D. +49 6221 5636439 vladimir.lozanovski@med.uni-heidelberg.de | |
Sub-Investigator: Vladimir J. Lozanovski, M.D. |
Study Director: | Peter Schemmer, Prof. Dr. med. | Heidelberg University | |
Principal Investigator: | Ingrid Herr, Prof. Dr. | Heidelberg University |
Responsible Party: | Peter Schemmer, Prof. Dr. med. Peter Schemmer, MBA, Heidelberg University |
ClinicalTrials.gov Identifier: | NCT01879878 |
Other Study ID Numbers: |
POUDER U1111-1144-2013 ( Other Identifier: WHO ) |
First Posted: | June 18, 2013 Key Record Dates |
Last Update Posted: | May 28, 2015 |
Last Verified: | May 2015 |
pancreatic adenocarcinoma broccoli sprouts sulforaphane palliative chemotherapy cancer stem cells |
Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms |